|
Market Closed -
NYSE
21:00:02 12/06/2026 BST
|
After hours
22:00:27
|
|
285.94 USD
|
-2.22%
|
 |
308.62 |
+7.93%
|
|
06-03 |
Bio-Rad Laboratories, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 08:45 AM
| | |
05-19 |
Bio-Rad Laboratories, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 08:30 AM
| | |
05-18 |
Bio-Rad Laboratories Draws Elliott Investment as Activist Investor Pushes for Turnaround
|
MT
| |
05-18 |
Elliott Investment Management LP Urges Improvement In Share Price And Value Creation for Shareholders
|
CI
| |
05-18 |
Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports
|
RE
| |
05-18 |
Activist investor Elliott builds stake in life-science tools supplier Bio-Rad Laboratories, WSJ reports
|
RE
| |
05-18 |
Activist Elliott Investment Management has built a sizable stake in Bio-Rad Laboratories - WSJ
|
RE
| |
05-15 |
Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says
|
MT
| |
05-11 |
Bio-Rad to Participate in Upcoming Investor Conferences
|
AQ
| |
05-08 |
Bio-Rad to Participate in Upcoming Investor Conferences
|
BU
| |
05-01 |
Bio-Rad Laboratories, Inc., Q1 2026 Earnings Call, Apr 30, 2026
| | |
04-30 |
Bio Rad Laboratories : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
|
PU
| |
04-30 |
Bio-Rad Laboratories Q1 Adjusted Earnings Fall, Revenue Rises
|
MT
| |
04-30 |
Bio-Rad: Q1 Earnings Snapshot
|
AQ
| |
04-30 |
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q1 Revenue $592.1M, vs. FactSet Est of $589.9M
|
MT
| |
04-30 |
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Posts Q1 Adjusted EPS $1.89 per Share, vs. FactSet Est of $1.97
|
MT
| |
04-30 |
Tranche Update on Bio-Rad Laboratories, Inc.'s Equity Buyback Plan announced on July 20, 2023.
|
CI
| |
04-30 |
Bio-Rad Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
04-30 |
Bio-Rad Reports First-Quarter 2026 Financial Results
|
BU
| |
04-16 |
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
|
BU
| |
04-07 |
Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375
|
MT
| |
02-13 |
UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating
|
MT
| |
02-12 |
Bio-Rad Laboratories, Inc., Q4 2025 Earnings Call, Feb 12, 2026
| | |
02-12 |
Bio-Rad Laboratories Q4 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours
|
MT
| |
02-12 |
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q4 Revenue $693.2M, vs. FactSet Est of $688.8M
|
MT
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
